Reata culls bardoxolone, ending decade of R&D on troubled kidney disease drug
10 May 2023
Reata’s long and winding road with bardoxolone appears to be over.
The Plano, TX-based biotech and partner Kyowa Kirin said Wednesday morning that they are scrapping development of the asset in chronic kidney disease programs, which include CKD caused by Alport syndrome, people with diabetic CKD and a rare, hereditary form of the disease.
With that, Reata expects to save more than $100 million previously set aside for the drug, a move that will push runway to the end of 2026, the company said in a presentation. Reata also disclosed a non-dilutive $275 million debt facility as part of its first-quarter
update
.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.